Article in Journal of cardiovascular development and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 5 institutions in 1 country.
Anna Wålinder ÖsterbergCrown Princess Victoria Children's Hospital, Linköping University Hospital and Division of Pediatrics, Department of Biomedical and Clinical Sciences, Linköping University, SE-58183 Linköping, Sweden.ORCID 0000-0002-5702-296X
Ingegerd Östman-SmithDepartment of Paediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-41680 Göteborg, Sweden.
Henrik GreenDepartment of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, SE-58185 Linköping, Sweden.ORCID 0000-0002-8015-5728
Cecilia GunnarssonDepartment of Clinical Genetics, Department of Biomedical and Clinical Sciences, Centre for Rare Diseases in Southeast Region of Sweden, Linköping University, SE-58183 Linköping, Sweden.
Mats FredriksonDepartment of Clinical and Experimental Medicine, Linköping University, SE-58183 Linköping, Sweden.ORCID 0000-0003-3067-8587
Petru LiubaPaediatric Heart Centre, Skåne University Hospital and Department of Clinical Sciences, Lund University, SE-22185 Lund, Sweden.
Eva FernlundCrown Princess Victoria Children's Hospital, Linköping University Hospital and Division of Pediatrics, Department of Biomedical and Clinical Sciences, Linköping University, SE-58183 Linköping, Sweden.ORCID 0000-0001-6508-9411
Linköping University · SELund University · SELinköping University Hospital · SESwedish National Board of Forensic Medicine · SEUniversity of Gothenburg · SE
Funding
Region Östergötland Clinical research project for trainees in Region Östergötland (RÖ-936968, RÖ-966208), Region Östergötland (RÖ -962620, RÖ-935433), ALF grants Region Östergötland (RÖ-966451, RÖ-974174), Medical research council of Southeast Sweden (FORSS-932208, FORSS-932
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Biomarkers and Proteomics in Sarcomeric Hypertrophic Cardiomyopathy in the Young-FGF-21 Highly Associated with Overt Disease. · full record | OpenQuestion